Brain Oxygen Metabolism and Hemodynamic Impairment in Multiple Sclerosis

多发性硬化症的脑氧代谢和血流动力学损伤

基本信息

  • 批准号:
    8539855
  • 负责人:
  • 金额:
    $ 51.95万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-09-15 至 2017-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system (CNS) and one of the most common causes of nontraumatic disability among young and middle-aged people. One of the hallmarks, however, is the progressive neurodegeneration that plays a key role in the progression of neurological disabilities. Little is known of the link between neuroinflammation and neurodegeneration. Recent biochemical studies suggested that there is defective oxygen metabolism in mitochondria due to increased nitric oxide (NO) as a result of vascular inflammation, which may play a crucial role in neuronal/axonal injury. In addition, NO is a strong mediator of neurovascular coupling that is responsible for increased blood supply during transient neural activation. In MS, the presence of a tonically high NO level (even during resting) may desensitize the vascular smooth muscle over time with a consequence of decreased vasodilatory capacity or cerebral vascular reactivity (CVR) and limited blood supply when neurons perform a demanding task. The Overarching Goals of this proposal are to detect and characterize abnormalities in oxygen consumption and vascular reactivity in early MS and identify tissues at risk using several advanced metabolic/vascular MRI techniques. These include a recently developed T2-Relaxation-Under-Spin-Tagging (TRUST) for the evaluation of global cerebral metabolic rate of oxygen (CMRO2) and a patient-comfortable blood-oxygen-level-dependent (BOLD) paradigm using CO2 inhalation to measure CVR. We will quantify CMRO2 and CVR abnormalities in patients with early relapsing-remitting (RR) MS and subsequent advanced stage of secondary progressive (SP) MS that are associated with clinical disability and disease progression. We hypothesize that oxygen metabolism abnormality in conjunction with impaired blood flow regulation is a key factor causing early degeneration. We also hypothesize that the combined functional index of CMRO2 and CVR has the potential to be an objective marker to predict neurodegenerative progression and its clinical outcome in MS. The Specific Aims are as follows: 1. To assess global CMRO2 abnormalities using TRUST MRI in patients with early RR and SP patients as compared with age/sex matched normal controls; 2. To measure CVR using inhalation of 5% CO2 and BOLD imaging in order to elucidate the nature of cerebrovascular dysfunction in MS patients; 3. To measure CVR and CMRO2 changes in healthy controls between groups with low and high intake of dietary nitrate (corresponding to higher NO level); 4. To determine longitudinal changes of CMRO2 and CVR in early RRMS patients and their relationship to imaging and clinical outcomes over a 5-year period. Health Relevance: By providing in vivo MRI confirmation of our working hypotheses, this application could have profound consequences for our understanding of disease pathogenesis and progression (neurological disability and cognitive decline) in MS, and for the future design of novel therapeutic strategies.
描述(由申请人提供):多发性硬化症(MS)是一种中枢神经系统(CNS)的慢性炎症性疾病,是青年和中年人非创伤性残疾的最常见原因之一。然而,其中一个标志是进行性神经变性,在神经功能障碍的进展中起着关键作用。人们对神经炎症和神经变性之间的联系知之甚少。最近的生化研究表明,由于血管炎症导致的一氧化氮(NO)增加,线粒体中存在氧代谢缺陷,这可能在神经元/轴突损伤中起关键作用。此外,NO是神经血管耦联的强介质,其负责在短暂神经激活期间增加血液供应。在MS中,当神经元执行要求高的任务时,高浓度NO水平(即使在休息期间)的存在可能随着时间的推移使血管平滑肌脱敏,导致血管舒张能力或脑血管反应性(CVR)降低和血液供应受限。该提案的总体目标是检测和描述早期MS中氧消耗和血管反应性的异常,并使用几种先进的代谢/血管MRI技术识别有风险的组织。其中包括最近开发的用于评价整体脑氧代谢率(CMRO 2)的T2-松弛-自旋标记(TRUST)和使用CO2吸入测量CVR的患者舒适血氧水平依赖性(BOLD)范例。我们将量化与临床残疾和疾病进展相关的早期复发缓解型(RR)MS和继发性进展型(SP)MS晚期患者的CMRO 2和CVR异常。我们推测氧代谢异常与血流调节受损是导致早期退行性变的关键因素。我们还假设CMRO 2和CVR的组合功能指数有可能成为预测MS神经退行性进展及其临床结局的客观标志物。具体目的如下:1.与年龄/性别匹配的正常对照相比,使用TRUST MRI评估早期RR和SP患者的总体CMRO 2异常; 2.采用5%CO2吸入法和BOLD显像法测定代谢综合征患者的CVR,以探讨代谢综合征患者脑血管功能障碍的本质。测量健康对照组在低和高膳食硝酸盐摄入组(对应于较高的NO水平)之间的CVR和CMRO 2变化; 4.确定早期RRMS患者CMRO 2和CVR的纵向变化及其与5年内成像和临床结局的关系。健康相关性:通过提供体内MRI证实我们的工作假设,这种应用可能对我们理解MS的疾病发病机制和进展(神经功能障碍和认知能力下降)以及未来设计新的治疗策略产生深远的影响。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Yulin Ge其他文献

Yulin Ge的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Yulin Ge', 18)}}的其他基金

In vivo insights of small vessel changes with age using USPIO-enhanced MRI
使用 USPIO 增强 MRI 观察小血管随年龄变化的体内变化
  • 批准号:
    10413130
  • 财政年份:
    2018
  • 资助金额:
    $ 51.95万
  • 项目类别:
In vivo insights of small vessel changes with age using USPIO-enhanced MRI
使用 USPIO 增强 MRI 观察小血管随年龄变化的体内变化
  • 批准号:
    10213150
  • 财政年份:
    2018
  • 资助金额:
    $ 51.95万
  • 项目类别:
Quantitative MR Imaging & Proton Spectroscopy in MS.
定量磁共振成像
  • 批准号:
    8676228
  • 财政年份:
    2013
  • 资助金额:
    $ 51.95万
  • 项目类别:
Brain Oxygen Metabolism and Hemodynamic Impairment in Multiple Sclerosis
多发性硬化症的脑氧代谢和血流动力学损伤
  • 批准号:
    8675294
  • 财政年份:
    2012
  • 资助金额:
    $ 51.95万
  • 项目类别:
Brain Oxygen Metabolism and Hemodynamic Impairment in Multiple Sclerosis
多发性硬化症的脑氧代谢和血流动力学损伤
  • 批准号:
    8439069
  • 财政年份:
    2012
  • 资助金额:
    $ 51.95万
  • 项目类别:
Brain Oxygen Metabolism and Hemodynamic Impairment in Multiple Sclerosis
多发性硬化症的脑氧代谢和血流动力学损伤
  • 批准号:
    9086437
  • 财政年份:
    2012
  • 资助金额:
    $ 51.95万
  • 项目类别:
Quantitative MR Imaging and Proton Spectroscopy in MS
MS 中的定量 MR 成像和质子能谱
  • 批准号:
    8210947
  • 财政年份:
    1991
  • 资助金额:
    $ 51.95万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 51.95万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 51.95万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 51.95万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 51.95万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 51.95万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 51.95万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 51.95万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 51.95万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 51.95万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 51.95万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了